

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-10. (canceled)

11. (previously presented) A vector comprising a polynucleotide of claim 27.

12. (previously presented) A vector comprising a non-native expression control sequence operably linked to a polynucleotide selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 32.

13. (previously presented) A host cell comprising a non-native expression control sequence operably linked to a polynucleotide selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 32.

14-18. (canceled)

19. (previously presented) A method for producing an anthrax toxin receptor, the method comprising the steps of:

transcribing a polynucleotide operably linked to an upstream expression control sequence, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 32, to produce an mRNA; and

translating the mRNA to produce the anthrax toxin receptor.

20. (original) A method as claimed in Claim 19, wherein the polynucleotide is operably linked to the expression control sequence in an expression vector, and wherein the expression vector is delivered into a host cell, the expression control sequence being operable in the host cell.

21. (original) A method as claimed in Claim 19, wherein at least one of the transcribing and translating steps are performed *in vitro*.

22-26. (canceled)

27. (currently amended) An isolated polynucleotide or complement thereof, the polynucleotide comprising a nucleotide sequence encoding ~~an~~ the amino acid sequence of SEQ ID NO:2.

28. (currently amended) An isolated polynucleotide or complement thereof, the polynucleotide encoding ~~an~~ the amino acid sequence selected from the group consisting of SEQ ID NO:2, amino acids 27-321 of SEQ ID NO:2, and amino acids 28-320 of SEQ ID NO:2.

29. (previously presented) The isolated polynucleotide of claim 27 comprising SEQ ID NO:1 from position 104 to 1207 or the complement thereof.

30. (currently amended) An isolated polynucleotide or complement thereof, the polynucleotide encoding ~~an~~ the amino acid sequence selected from the group consisting of amino acids 41-227 of SEQ ID NO:2, amino acids 42-222 of SEQ ID NO:2, and amino acids 44-216 of SEQ ID NO:2.

31. (currently amended) The isolated polynucleotide of claim 30 wherein the polynucleotide encodes ~~an~~ the amino acid sequence selected from the group consisting of amino acids 41-227 of SEQ ID NO:2 and amino acids 42-222 of SEQ ID NO:2.

32. (currently amended) An isolated polynucleotide or complement thereof, the polynucleotide encoding a soluble polypeptide that comprises ~~an~~ the amino acid sequence selected from the group consisting of amino acids 27-321 of SEQ ID NO:2 and amino acids 28-320 of SEQ ID NO:2.

33. (previously presented) The isolated polynucleotide of claim 32, wherein the polynucleotide encodes a soluble polypeptide that comprises amino acids 27-321 of SEQ ID NO:2.

34. (previously presented) The vector of claim 12, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 33.

35. (previously presented) The host cell of claim 13, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 33.

36. (previously presented) The method of claim 19, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 33.